Meridian Bioscience, Inc. Profile Avatar - Palmy Investing

Meridian Bioscience, Inc.

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates thro…
Medical - Diagnostics & Research
US, Cincinnati [HQ]

Ratios

14 Sheets · From 2022 to 2009
Configuration
Margins, Growth Rates In %
Ratio 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Profitability
Gross Margin
62.58 61.87 62.17 63.31 64.15 62.09 62.56 65.17 62.18 61.09 58.86 61.60 63.27 56.56
Profit Margin
22.09 18.63 16.80 19.23 20.16 18.40 18.24 16.44 10.74 11.17 12.13 18.21 22.46 12.75
Operating Margin
32.90 28.77 25.06 28.41 30.38 27.75 28.77 26.20 18.62 14.79 16.27 24.18 29.27 16.67
EPS Growth
8.00 -18.52 - - 22.73 13.58 -8.70 1.19 -9.41 -33.77 9.80 1.79 87.72 51.40 -40.74
Return on Assets (ROA)
21.00 17.22 17.26 20.68 21.52 19.64 19.39 12.80 8.63 9.49 7.49 11.40 15.88 9.17
Return on Equity (ROE)
23.75 19.40 19.37 23.38 24.53 21.58 21.43 19.36 12.71 13.60 12.77 18.65 21.75 11.54
Return on Invested Capital (ROIC)
23.49 19.28 19.15 23.18 24.51 21.69 21.81 14.54 9.87 10.99 9.47 14.71 18.35 10.71
Solvency
Equity Ratio
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
Debt/Assets
- - - - - - - - - - - - - - 23.18 21.88 19.96 23.30 17.42 14.66 6.69
Debt/Equity
- - - - - - - - - - - - - - 35.06 32.22 28.61 39.71 28.52 20.08 8.41
Debt/EBITDA
-100.65 -82.19 -51.14 -56.10 -70.31 -74.64 -82.90 19.14 -5.25 -24.06 30.89 22.65 15.01 -70.12
Debt/Capitalization
- - - - - - - - - - - - - - 25.96 24.37 22.24 28.42 22.19 16.72 7.76
Interest Debt per Share USD
- - - - - - - - - - - - - - 1.41 1.33 1.21 1.81 1.70 1.54 0.73
Debt Growth
- - - - - - - - - - - - - - - - -6.36 -8.17 51.10 -6.87 -6.64 -53.04
Liquidity
Current Ratio
699.30 664.59 591.94 523.18 525.68 820.88 805.54 561.74 584.94 575.24 692.17 308.79 408.86 363.41
Quick Ratio
527.08 423.72 317.54 302.11 324.68 482.56 499.82 329.31 376.54 381.00 468.61 175.21 219.14 222.06
Cash Ratio
322.53 267.75 154.78 171.12 204.04 313.41 327.67 209.23 249.36 247.23 298.35 101.88 105.54 140.55
Operating Cash Flow Ratio
100 200 100 200 200 200 200 100 100 100 100 - - 100 100
Turnover
Inventory Turnover
238.32 194.98 184.85 200.95 194.18 201.69 203.67 151.58 183.01 197.91 208.72 159.02 151.93 213.32
Receivables Turnover
549.55 648.12 642.90 717.62 720.64 812.81 742.10 723.50 689.79 660.47 564.52 658.67 593.44 705.02
Payables Turnover
804.10 1,220.89 1,089.13 1,098.79 1,209.62 1,441.58 1,097.62 895.44 983.78 1,327.64 1,142.43 813.93 997.76 814.58
Asset Turnover
95.05 92.39 102.72 107.54 106.75 106.73 106.30 77.87 80.38 84.96 61.76 62.59 70.69 71.91
Coverage
Interest Coverage
- - - - - - - - - - - - - - 5,727.76 2,276.61 2,077.89 1,681.18 2,329.94 4,953.89 4,668.29
Asset Coverage
- - - - - - - - - - - - - - 300 300 400 300 300 400 1,000
Cash Flow Coverage (CFGR)
- - - - - - - - - - - - - - 63.78 75.68 69.32 47.26 67.94 101.43 266.05
EBITDA Coverage
- - - - - - - - - - - - - - 6,400 2,800 2,600 2,200 2,800 5,700 6,000
Dividend Coverage
-100 - - - - -100 -100 -100 -100 - - - - -100 -200 - - - - - -
Time Interest Earned (TIE)
200 100 100 100 100 100 100 100 100 100 100 100 100 100
Market Prospects
Dividend Yield
2.60 3.38 4.83 4.01 3.22 4.47 4.68 4.15 4.02 3.35 2.61 - - - - - -
Earnings Yield
3.24 3.01 4.19 4.29 3.90 4.74 4.99 3.98 3.57 3.77 5.99 6.30 8.43 3.06
Price/Earnings (P/E)
3,083.59 3,325.19 2,388.48 2,332.76 2,561.56 2,110.75 2,004.41 2,514.42 2,798.57 2,649.60 1,669.72 1,587.27 1,185.87 3,268.33
Price/Book (P/B)
732.50 645.06 462.63 545.34 628.34 455.41 429.47 486.79 355.74 360.23 213.18 296.05 257.93 377.03
Price/Sales (P/S)
681.28 619.62 401.23 448.57 516.31 388.36 365.64 413.28 300.49 295.88 202.53 289.00 266.37 416.70
Price/Cash Flow (P/CF)
3,108.93 2,838.76 2,853.82 1,834.01 2,192.39 1,916.62 1,664.06 2,177.08 1,458.80 1,816.70 1,136.20 1,528.04 1,266.42 1,684.90